Aurobindo Pharma gets US FDA OK for alprazolam extended-release

- Last updated on GMT

Related tags: Controlled substances act

Drug maker Aurobindo Pharma has been cleared to make a generic equivalent of Pfizer’s CNS drug Xanax XR by the US FDA.

According to a filing on the Bombay Stock Exchange the firm has received final approval from the US Food and Drug Administration (FDA) to make and sell alprazolam extended-release tablets in four different doasage strengths.

Aurobindo told India’s Business Standard that: "The product has a market size of approximately $26.5 million for the twelve months ending September, 2010, according to IMS and will be launched soon.

The news follows just weeks after the firm announced it is considering demerging its API and formulation businesses to unlock value and better serve clients.

Related news

Show more

Related product

The Effect of Tamping Force on Bi-Layer Tablets

The Effect of Tamping Force on Bi-Layer Tablets

JRS PHARMA | 15-Aug-2020 | Technical / White Paper

Formulation of bi-layer or multi-layer tablets enables the combination of two or more drugs that may be incompatible or maybe intended for delivery at...

Related suppliers

Follow us

Products

View more

Webinars